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INTRODUCTION
Premature, low-birth-weight infants in the neonatal 
intensive care unit (NICU) can lose blood glucose 
homeostasis due to immaturity of endogenous 
regulatory systems and the stress of their condition. 
Hyperglycemia occurs in 40-80% of premature, low 
birthweight infants. This condition has been linked to 
worsened outcomes in preterm neonates, including an 
increased risk of further complications, such as sepsis, 
increased ventilator dependence, retinopathy of 
prematurity, hospital length of stay and mortality
Often, glucose restriction is used to control high blood 
glucose levels. However, this restriction also deprives 
the neonate of crucial energy required to promote 
growth. Continuous insulin infusion has thus been 
proposed as a solution to reduce plasma glucose 
concentrations and optimize nutrition in these small 
infants. 
The pathogenesis of hyperglycemia in critically ill adults 
and preterm may differ. The mechanisms responsible 
for hyperglycemia in preterm infants are related to 
immaturity of the glucose regulatory system, in addition 
to clinical stress.
A model of the fundamental glucose regulatory 
dynamics in neonates can provide insight about the 
metabolic state of the patient. In-silico virtual trials were 
used to design optimal insulin therapy regimes for this 
vulnerable patient group, and piloted in 24-hour clinical 
trials.
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MODELS AND METHODS
A metabolic computer system model, clinically validated in adult intensive care 
patients and virtual trials using neonatal data, is used to provide tight control in 
very low birth weights infants.
Seven clinical trials up to 24 hours each were performed based on initial blood 
glucose over 10 mmol/L to initiate insulin.
Insulin infusions were modulated to hit a pre-determined target based on 
measurements every 2-3 hours (max 12 measurements/day). The overall goal 
was to control blood glucose in a 4-7 mmol/L band. A stochastic model ensured 
the risk of blood glucose below 4 mmol/L was less than 5% for each intervention. 
Ethics approval was granted by the Upper South Regional Ethics Committee.
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Pilot trial cohort clinical details.
RESULTS: CLINICAL TRIALS
Model-fitted insulin sensitivity during trials. Each line represents 
the hourly evolution of patient sensitivity to exogenous insulin.
Within the relatively small study 
population, a 2.3x spread of dextrose 
infusion rates were used, and an 8.9x 
spread of insulin sensitivity was 
computed. In response, the controller 
used a 7.6x spread of median insulin 
infusion rates.
Normoglycemia in a 4-7 mmol/L band was achieved in all cases. Median initial 
blood glucose was 10.1 mmol/L (Range: 7.4 – 14.4 mmol/L). Over all trials 
median blood glucose was 6.9 (IQR: 5.6 – 7.9, 90%CI: 4.6 – 11.2) mmol/L over 
74 measurements. The minimum blood glucose was 3.8 mmol/L.
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Clinical BG results for pilot trial patients 2 (top panel) and 3 (bottom 
panel). Green areas denote stochastic model 5%-95% BG prediction 
confidence interval.
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Patient
Gestational 
age at birth 
[weeks]
Age at start of 
trial [days]
Birth weight 
[g]
Insulin usage 
before trial 
[hours]
A 24.4 7 685 15.3
B 27.3 9 770 15.0
C 25.4 1 720 3.2
D 25.4 7 785 91.6
E 25.9 4 540 2.2
F 27.0 2 900 0.0
G 25.0 6 995 11.5 Controller implementation overview.
mg/kg/min kcal.kg.day
A 7.1 40.6 0.0 0.025 7.7 1.04 8.7 6.9 2.1 0.45
B 9.4 54.4 5.0 0.040 6.7 1.16 12.3 4.1 1.7 1.25
C 4.1 23.3 0.0 0.068 8.7 1.19 14.4 5.2 1.7 0.14
D 9.6 55.0 3.0 0.052 6.5 1.08 8.0 5.0 2.5 0.7
E 6.8 39.1 11.0 0.116 9.0 1.12 12.6 6.5 2.1 0.2
F 8.2 47.5 4.5 0.069 7.0 1.23 14.5 3.8 1.7 0.5
G 9.4 54.3 2.0 0.191 8.7 1.17 14.7 5.3 1.9 0.14
Patient Min. BG [mmol/L]
Measurement 
period, hours
Median insulin 
sensitivity 
[L/(mU.min)]
Median 
insulin rate 
[U/kg/hr]
Median dextrose rate Geometric 
BG mean 
[mmol/L]
Geometric 
BG StDev 
[mmol/L]
Max. BG 
[mmol/L]
Total 
EBM 
[mL]
Clinical glycemic variables during trials. Infusion rates are computed as hourly averages. 
BG mean and standard deviation are computed using lognormal statistics. EBM = Expressed Breast Milk.
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Per-patient BG concentration during computerised insulin dosing. 
The shaded region represents the 4-7 mmol/L target band.
Stochastic model forecasts drove 
controller decisions for more insulin 
resistant and/or dynamic patients, 
preventing episodes of hypoglycaemia.
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•Change in insulin 
sensitivity contained 
•Insulin infusion rate 
adjusted 
•More aggressive control 
may have created hypo 
event for this patient 
•Controller tolerated 
period of higher BG to 
balance risk of changes 
in patient condition. 
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Overall cohort BG prediction error 
was 7.6% (0.54 mmol/L) during 
clinical trials. Distribution of BG 
prediction errors revealed 69% 
and 84% of BG measurements 
within ±10% and ±20% of 
forecasted concentration.
[%] [mmol/L]
A 19.20% 1.47 33% 83%
B 8.60% 0.52 31% 85%
C 7.60% 0.77 80% 90%
D 8.40% 0.53 33% 100%
E 6.40% 0.48 100% 100%
F 8.50% 0.72 50% 83%
G 5.90% 0.44 92% 100%
Whole cohort 7.60% 0.54 62% 92%
Patient
Median BG prediction 
error (absolute) BG within IQR forecast range
BG within 5%-95% 
forecast range
BG prediction accuracy and stochastic model prediction coverage.
0 0.5 1 1.5 2 2.5
0
2
4
6
8
10
12
14
BG prediction error [mmol/L]
#
 
p
r
e
d
i
c
t
i
o
n
s
0 10 20 30 40
0
2
4
6
8
10
12
14
BG prediction error [%]
#
 
p
r
e
d
i
c
t
i
o
n
s
#
 
p
r
e
d
i
c
t
i
o
n
s
#
 
p
r
e
d
i
c
t
i
o
n
s
#
 
p
r
e
d
i
c
t
i
o
n
s
BG prediction errors during trials (expressed as absolute concentration in 
left panel, and percentage of measured BG concentration in right panel).
Comparison with simulated trial 
results indicated level of control 
matched predictions, despite 
significantly insulin-resistant 
clinical cohort.
Distribution of insulin 
sensitivity between 
clinical trial patients 
(n=7) and matched 24- 
hour simulated trials on 
retrospective cohort 
(n=7).
Distribution of BG between clinical trial patients (n=7) and 
matched 24-hour simulated trials on retrospective cohort (n=7).
